chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Information has been received from a 40 year old female with "mild asthma" who was vaccinated with a dose of PNEUMOVAX 23 vaccine. There was no concomitant medication. After getting the vaccine, the patient's arm swelled so it looked like she had another muscle on the top of her muscle. She had lumps and bumps on a 4" x 4" area at the injection site. There as a "dull red streak" on her arm. She had a fever of 102, chills, bodyaches. On 04-OCT-2009 the patient recovered. Additional information has been requested.
Feeling sick; Run a temperature; He still has been running a temperature of 102.3; Real bad headache; Little difficulty in breathing; Tired; This is a spontaneous report from a contactable consumer or other non hcp. A 63-year-old male patient received bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Formulation: Solution for injection, (Batch/Lot Number: EN6198), via an unspecified route of administration on 23Feb2021 12:00, unknown dose, as single dose for covid-19 immunization. The patient's medical history included congestive heart failure, diabetes mellitus and peripheral neuropathy. Concomitant medications included gabapentin taken for an unspecified indication, carvedilol (COREG) taken for an unspecified indication. Patient takes short and long-acting insulin for diabetes mellitus. On an unknown date, the patient experienced sickness, run a temperature; he has been running a temperature of 102.3, real bad headache, little difficulty in breathing and, fatigue. The patient underwent lab tests and procedures which included body temperature: 102.3. The reporter stated he had 15 to 20 percent ejection fraction and he takes insulin short acting and long acting, but there is no further information. Therapeutic measures were taken as a result of the events with Tylenol. The outcome of the events was unknown.  No follow-up attempts are possible. No further information is expected.
Large red localized reaction an inch below vaccination site. Has continued to grow in size even after taking a Benadryl and Advil.   Reaction looks somewhat like cellulitis.
Left armpit swelling after shot. But since January I?ve had random flare ups of pain and swelling in both armpits.
18hrs post vaccine significant headache primarily forward and behind sinuses; 22-23 hrs post injection onset of significant fatigue and 'blah' feeling; 24hrs post injection extreme fatigue and lethargy beginning of 'cant get warm' but not chills, had to wear a jacket in 80degree weather; 36hrs post injection alternating chill/hot; 42 hrs post injection feeling more normal, less headache, not temp sensitive
SkinRash little red, raised bumps from right lower arm to bicep and left forearm, chest and neck Narrative:  Other Relevant History:
a patient in a nursing home facility that tested positive after receiving the first COVID vaccine; a patient in a nursing home facility that tested positive after receiving the first COVID vaccine; This is a spontaneous report from a contactable Nurse via a Pfizer-sponsored program. A male patient of an unspecified age received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration on an unspecified date at first single dose for COVID-19 immunization. The patient medical history was not reported. The patient's concomitant medications were not reported. The patient tested positive after receiving the first covid vaccine. The patient is asymptomatic. The reporter just need to know if she can give this man the second vaccine. Outcome of the event was unknown.  Information on the lot/batch number has been requested.; Sender's Comments: Based on available information, a possible contributory role of BNT162B2 cannot be excluded for reported events.
No additional AE; vaccine was administered after a temperature excursion; This spontaneous report was received from a nurse concerning a patient of unknown age and gender. Information on pertinent medical history, concomitant medications and drug reactions/allergies was not reported.   On 14-JAN-2022, the patient was vaccinated with an improperly stored varicella virus vaccine live (oka/merck) (VARIVAX) (lot # U022321, expiration date 15-JUL-2023) 0.5 milliliter for prophylaxis (dose number, route of administration and location of administration were not reported).  The vaccine was exposed to a temperature of -14.1 C for 12 minutes. There were no previous temperature excursions. No adverse effects were reported.
Seizure in a person who had never had a seizure before. Healthcare provider/pediatric neurology could not identify reason for seizure.
Administer Expired vaccine; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Administer Expired vaccine) in a 71-year-old patient of an unknown gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 031B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 11-Nov-2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 11-Nov-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (Administer Expired vaccine). On 11-Nov-2021, EXPIRED PRODUCT ADMINISTERED (Administer Expired vaccine) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant product information was not provided.  Reporter also stated that the vaccines were stored in freezer and they took out one to two vials and  placed in fridge each day as needed.  Reporter stated that no treatment was given to patients.
Patient arrived at pharmacy to get pneumonia "Booster". Tech used screening tool to screen patient; and patient was given PREVNAR. Received PREVNAR 13 in 2015 already.
Redness, hot to touch rash that has spread past immediate injection site- probably about 10 cm. Noticed about 30-36 hours after the injection.
A report was received from a healthcare professional on 5 November 2003 concerning a 56 year old female vaccinee who experienced a 3-4 inch red area around the injection site and itches on the same day as receiving Fluvirin on 4 November 2003. On 4 November 2003 the vaccinee experienced a 3-4 inch red area around the injection site and itches.  The vaccinee had not recovered at the time of the report. There was insufficient information to determine the reporter's causality assessment. Follow up pending.
Patient is a 62 y.o. female with past medical history of COPD, diastolic CHF, former chronic tobacco use, amyloidosis of the lung, OSA intolerant to CPAP, type 2 diabetes, hypertension, hyperlipidemia, CKD stage III who presents to the ER with complaints of cough, shortness of air, and hypoxia.   Patient reports that over the past 4 days she has had increasing shortness of air.  Apparently recently diagnosed with COVID-19 as of 10/26/2021.  Denies really having any major symptoms until the past 4 days.  Received monoclonal antibody therapy outpatient.  Reports increasing shortness of air tonight rated 7 out of 10 in severity with increased wheezing.  Worse with exertion.  Improved with rest.  Patient noted to be 75% on room air at home.  Now requiring 2 L nasal cannula.
No adverse event, patient received regular 0.5ml of Flu zone instead of receiving high dose 0.7 Flu  Zone.  Patient is aware of side effects and allergic reactions; advised patient if he experiences any allergic reactions to call 911 or get to the hospital.
pt recv vax & as late as 7 days p/vax pt devel localized rash @ inj site & erythema;
Multiple patients (25) were vaccinated with lot number FK9894, but the number was erroneously entered in system and on vaccine card as FK9729.
Ongoing dizziness, dysautonomia, fatigue. Has been treated for possible Meniere's disease and for anxiety. Recurrent MRSA skin infections since 9/2008.  3/20/09 Received PCP medical records which included hospital medical records, Neuro, ENT & Cardio consults. FINAL DX: chronic migraines; chronic dizziness; depression; anxiety; orthostatic intolerance; peripheral vertigo; active Meniere's disease, cochleovestibular; tinnitus; possible vestibular migraine; paced vertiginous syndrome; partial dysautonomia probably post viral; orthostatic intolerance grade 1.  Records reveal patient experienced episodes of dizziness 9/19/07, near blacking out w/position changes.  Already seeing Neuro at that time for migraines.  PO fluids encouraged. RTC 11/28/07 for BCP when minocycline d/c for acne.  RTC 1/21/08 w/anxiety, depression, anger x 1 year.  Tx w/antidepressants & referred for counseling.  RTC 5/12/08 feeling better but still anxious; meds adjusted.  RTC 9/24/08 w/insect bite left inner thigh & cough.  Dx w/cellulitis left leg & URI.  Tx w/oral antibiotics.  RTC 9/25/08 w/worsening cellulitis, dizziness, dysautonomia.  Tx w/IM antibiotics & given FluMist.  RTC 9/26/08 w/worsened cellulitis/early abscess & admitted to hospital 9/26-9/29/08.  Tx w/Vanco & developed red man's syndrome, chest pain. C/S (+) MRSA.  Recurred 10/29 & again 1/5/09 & tx w/oral antibiotics. Missed several days of school due to autonomic instability symptoms. RTC 2/20/09 w/sore throat, HA, abdominal pain, dizziness.  Dx w/abdominal pain, dizziness & pharyngitis.  Neuro consult 11/12/07-12/22/08. FINAL DX: chronic migraines; chronic dizziness; dysautonomia; depression; anxiety; orthostatic intolerance.  ENT consult 2/1-4/21/08. FINAL DX: peripheral vertigo; active Meniere's disease, cochleovestibular; tinnitus; possible vestibular migraine; dysautonomia.  Cardio consult 4/11-5/15/2008 FINAL DX: paced vertiginous syndrome; partial dysautonomia probably post viral; orthostatic intolerance grade 1; anxiety
Left arm soreness, fatigue, tactile fever, muscle aches (neck/shoulders/back)
Exposed to someone with Covid-19; This spontaneous case was reported by a consumer and describes the occurrence of EXPOSURE TO SARS-COV-2 (Exposed to someone with Covid-19) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On 10-Feb-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 20-Feb-2021, the patient experienced EXPOSURE TO SARS-COV-2 (Exposed to someone with Covid-19). At the time of the report, EXPOSURE TO SARS-COV-2 (Exposed to someone with Covid-19) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Antibody test: positive (Positive) Antibody IgG test-positive.         Lab data included Rapid antigen test-negative, antibody IgG test-positive, swab test-awaiting results.  Concomitant product use was not provided by the reporter.  No treatment medication was reported.
Sore throat, painful eyes, body aches, tightening in chest, back pain over kidneys, fever, vomiting legs weak, almost blacked out.
Patient called Public Health, report she has been experiencing , "a pounding heart beat, time is moving slowly, and I feel dizzy, I think it is anxiety."  Patient expressed some concern for cardiac issues, so this RN referred to UC or ER.
Information has been received from a physician concerning an 83 year old male who, "sometime last week", on approximately 01-DEC-2007, was vaccinated with a first dose of zoster vaccine live (Oka/Merck).  Subsequently the patient developed a 4 to 5 inch radius rash which appeared to be a case of shingles.  The patient was hospitalized but the specifics were unknown.  No product quality complaint was involved.  No other information was provided.  Additional information has been requested.
fever; body aches; Fatigue; This non-serious case was reported by a consumer via interactive digital media and described the occurrence of fever in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.  On an unknown date, the patient received the 1st dose of Shingles vaccine. On an unknown date, an unknown time after receiving Shingles vaccine, the patient experienced fever (Verbatim: fever), general body pain (Verbatim: body aches) and fatigue (Verbatim: Fatigue).  The outcome of the fever, general body pain and fatigue were not reported.  It was unknown if the reporter considered the fever, general body pain and fatigue to be related to Shingles vaccine.  It was unknown if the company considered the fever, general body pain and fatigue to be related to Shingles vaccine.  Additional Information: GSK Receipt Date: 17-Sep-2023 This case was reported via interactive digital media. The patient reported that last month before reporting he/she had the first dose, and it went badly. The patient had fever, body aches, fatigue, but stated that after reading 10 things that you get with shingles, it was worth having gone through the effects of the vaccine. In October, patient was going to receive for the second dose. The follow up could not be possible as no contact details were available.
Numbness of pinky and ring finger; This is a spontaneous report from a contactable other healthcare professional (patient).  A 32-year-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE), lot number not reported, via an unspecified route of administration from 15Jan2021 06:30 to 15Jan2021 06:30 as SINGLE DOSE for COVID-19 immunisation.  The patient's medical history and concomitant medications were not reported.  The patient experienced numbness of pinky and ring finger on an unspecified date with outcome of unknown. Therapeutic measures were taken as a result of numbness of pinky and ring finger which includes prednisone. The patient is not pregnant. The patient was not tested with COVID prior and post vaccination.  Information on the Batch/Lot number has been requested.
This spontaneous report as receiving from a 76 year old female consumer with high blood pressure and pulmonary hypertension refers to herself. The patient did not have drug reactions/allergies. In August 2010 the patient was vaccinated with ZOSTAVAX (1 time vaccine, lot number not provided) subcutaneously. Concomitant therapies included TRACLEER for pulmonary hypertension. In December 2012 the patient got shingles after she had received the ZOSTAVAX vaccine. She also stated that she got the shingles, without them appearing openly on her. She said they were located in her right rib cage under her breast going onto her back side. She also stated in July 2013 she had had itching on her left leg in the front side that went from her knee up to her groin. LYRICA was given for adverse events. No lab diagnostics studies were performed. The patient had sought medical attention. The outcome of adverse events was unknown. Additional information has been requested.
Palpitations, chest pain, arm pain, headaches, dizziness, nausea, vomiting, fatigue, shortness of breath, presyncope, syncope, heartburn, blurred vision, tachycardia, pressure in head, elevated blood pressure. Symptoms worsened after 2nd covid vaccine.
Vaccinee stated while she was sitting in observation area she felt "cold" she was "shaking" her heart was "racing" and she had a "metal taste" in her mouth and felt a little short of breath. At 12:53 pm vitals 20 RR 02 sat 99% on RA HR 71 and BP 179/100 on L arm and 164/103 on R arm.  Vaccinee stated her normal blood pressure systolic in the 120's-130's.  HRR, lungs clear and no signs/symptoms of respiratory distress.   Vaccinee also reported anxiety.  At 12:58pm gave 25mg of liquid Benadryl.  Vaccinee called off work at SNF where worked as CNA.  Vaccine did not want to go to ER due to cost.  Monitored in clinic.  1:01pm RR 20, 02 sat 99% HR 76 BP 172/109 L.  Still no s/s of respiratory distress, feeling cold on and off. 1:17 pm RR 20 O2 sat 98% HR 72 B/P 184/100 L.  No other changes.  Offered second dose of Benadryl, vaccine refused. Still refused ER.  1:39pm RR 20 O2 sat 99 HR 67 BP 174/107 L.  Writer had vacinee call son and have son pick her up.  Lives with son.  Advised to go to ER or call 911 if symptoms worsen.  Also advised to see PCP if continued high blood pressure.
Headache; Fever; Fatigue; This spontaneous case was reported by a consumer and describes the occurrence of HEADACHE (Headache), PYREXIA (Fever) and FATIGUE (Fatigue) in a 77-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 012L20A) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced HEADACHE (Headache), PYREXIA (Fever) and FATIGUE (Fatigue). At the time of the report, HEADACHE (Headache), PYREXIA (Fever) and FATIGUE (Fatigue) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Body temperature: increased (High) not higher than 100F.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were provided by the reporter Treatment information was not provided by the reporter   Most recent FOLLOW-UP information incorporated above includes: On 08-Feb-2021: Updated Reporter's address, patient demographics (age at the time of event, date of birth) and suspect drug batch no. and anatomical location
Hair loss; Tiredness; Nausea; Headache; Very strong reaction/very sick and felt terrible; Couldn't eat; This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of ILLNESS (Very strong reaction/very sick and felt terrible), DECREASED APPETITE (Couldn't eat), ALOPECIA (Hair loss), FATIGUE (Tiredness) and NAUSEA (Nausea) in a 68-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 012M20A and 012LZ0A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.   On 16-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 13-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 13-Feb-2021, the patient experienced ILLNESS (Very strong reaction/very sick and felt terrible), DECREASED APPETITE (Couldn't eat), FATIGUE (Tiredness), NAUSEA (Nausea) and HEADACHE (Headache). On an unknown date, the patient experienced ALOPECIA (Hair loss). The patient was treated with CORTISONE for Hair loss, at an unspecified dose and frequency. On 20-Feb-2021, ILLNESS (Very strong reaction/very sick and felt terrible), DECREASED APPETITE (Couldn't eat), FATIGUE (Tiredness), NAUSEA (Nausea) and HEADACHE (Headache) had resolved. At the time of the report, ALOPECIA (Hair loss) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Concomitant product information was not provided.  The consumer visited a dermatologist on unknown date due to hair loss experienced several weeks after the second dose of the vaccine. Bloodwork was drawn to rule out other diseases, no results provided.  Treatment included , and a topical ointment.   This case was linked to MOD-2021-101556 (Patient Link).
Pt requested 3rd dose of Moderna (0.5ml) and was given booster dose (0.25ml).
This spontaneous report was received from a registered nurse, referring to a 18 week old patient of unknown gender. On 20-JUL-2017, the patient was administered with a dose of ROTATEQ (lot # M045545, exp. date: 10-JUN-2018, oral) for prophylaxis (product use in unapproved population). No adverse effects were reported. No additional information was provided.
19MAR92 recvd Recomb; 21MAR92 general malaise all day; evening-devel aching, nausea & diarrhea; 22MAR92-25MAR92 sx continued & resolved on 25MAR92; no known tx;
Received MMR on 02/25/2003, 9 days later child has rash and on the next day child has fever of 102 degrees F. Rash lasted about 1 1/2 weeks and fever started after rash. No cough, coryza (runny nose) or conjunctivitis. May be vaccine related.
1/27/22 pt entered the hosp for scheduled esophagectomy; metastasis to lymph nodes; 2/2/22 pt found to be positive for COVID; 2/15/22 pt intubated for hypoxic respiratory failure; sputum culture grew Klebsiella pneumoniae; 2/18/22 self extubated; developed COVID ARDS, increase in O2 requirements; intubated and sedated; family decided to transition pt to Comfort Measures with DNR; pt expired in the hospital
Pt presented with redness on his torso and reported having a fever the night after receiving influenza vaccine.  Pt referred to primary care provider.
Patient stated she started feeling poorly the night of her vaccination. Symptoms included fever of 100.8F and chills. She also noticed her left arm (arm of vaccination) became very itchy. After the itchiness subsided hours later, she noticed a tight, swollen feeling at the site of injection that was painful. She stated that today 4-23-2021, 8pm, that she is feeling better and her fever and chills have subsided. She still feels tightness and her deltoid area is swollen. We talked about how these symptoms can happen with vaccination and she will continue to use otc pain reliever to help manage painful symptoms. She asked me to submit reaction to VAERS as reaction worried her and she wanted her experience to help with the research and information that we are obtaining about this vaccine to help other people.
Chest pains (Every Day Since), Loss of Mental Focus (Every Day Since), Random Body Rashes and Persistent Itch (Lasted Over Two Months), Extreme Lack of Energy (Continually Since Injection), Loss of Proper Digestion (Diarrhea & Constipation, Continually Since Injection).
Vaccine administered at inappropriate site; Dizzy; Anxious; Nausea; This is a spontaneous report from a contactable pharmacist. A 49-year-old female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6205) via intramuscular route of administration in the left leg on 01Mar2021 (at the age of 49-years-old) as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. Prior to vaccination, it was unknown whether the patient was diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 01Mar2021, the patient experienced dizzy, anxious and nausea. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were taken as a result of the events and included treatment with ondansetron. Since the vaccination, it was unknown whether the patient had been tested for COVID-19. The clinical outcome of the events dizzy, anxious and nausea were recovered on an unknown date in Mar2021.   No follow-up attempts are possible. No further information is expected.
Swelling, warmth and mild pain over left upper extremity in the area of injection of pneumonia vaccine. 102 fever. Sulfamethoxazole-trimethoprim (BACTRIM DS) 800-160 mg per tablet. Prednisone (DELTASONE) 20 MG tablet. F/U if no improvement or worsening.